Last reviewed · How we verify

NCT04427592: percreta

New Conservative Technique for Placenta Accreta Spectrum

Completed NA Last updated 6 December 2023
What this trial tests

NA trial testing ultrasound in Placenta Accreta Spectrum in 159 participants. Completed in 20 May 2023.

Timeline
28 July 2020
Primary endpoint
20 April 2023
20 May 2023

Quick facts

Lead sponsorAlexandria University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment159
Start date28 July 2020
Primary completion20 April 2023
Estimated completion20 May 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Alexandria University

Who can join

Adults 19 to 40, female only, with Placenta Accreta Spectrum. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

participants diagnosed as placenta accreta spectrum were subjected to cesarean delivery. Investigators manually detected a plan of cleavage through which the placenta was separated followed by closure of defective placental bed. Data were collected about the outcome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ultrasound

Trials testing the same drug.

Other recruiting trials for Placenta Accreta Spectrum

Currently open trials in the same condition.

Other Alexandria University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04427592.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing